[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant appreciation of the Swiss franc

Roche’s 2026 outlook calls for Group sales growth in the mid single digits (CER) and core EPS growth in the high single digits (CER). The company also expects to further increase its dividend in Swiss francs, reinforcing a shareholder-return bias. Overall guidance suggests steady earnings compounding into 2026.

Analysis

Roche’s 2026 outlook calls for Group sales growth in the mid single digits (CER) and core EPS growth in the high single digits (CER). The company also expects to further increase its dividend in Swiss francs, reinforcing a shareholder-return bias. Overall guidance suggests steady earnings compounding into 2026.